RNAi JNJ-3989 + CAM-N JNJ-6379 + NA

StephenW

First Clinical Experience with RNA Interference-based Triple Combination Therapy in Chronic Hepatitis B:JNJ-3989, JNJ-6379 and a Nucleos(t)ide Analogue             AASLD 2019 Nov 8-12 Boston Man-Fung Yuen1, Stephen Locarnini2, Bruce Given3, Thomas Schluep3, James Hamilton3, Michael Biermer4, Ronald Kalmeijer5, Maria Beumont5, Oliver Lenz4, Gavin Cloherty6, Kathy Jackson2, Carlo Ferrari7, Ching Lung Lai1,Kevin Sze-Hang Liu1, Lung-Yi Mak1, Danny Ka-Ho Wong1, Wai-Pan To1, Kwan-Lung Ko1, Robert G. Gish81The University of Hong Kong, Hong Kong, China; 2Victorian Infectious Diseases Reference Laboratory, Victoria, Australia; 3Arrowhead Pharmaceuticals, Pasadena, CA, USA; 4Janssen Pharmaceuticals BV, Beerse, Belgium; 5Janssen R&D, Titusville, NJ, USA; 6Abbott Diagnostics, Abbott Park, IL, United States;7University of Parma, Parma, Italy; 8Hepatitis B Foundation, Doylestown, PA, USA